Current Clinical Studies and registry trials

Helping Make a Difference

Agendia’s extensive clinical trials and research collaborations have produced numerous retrospective and prospective validation studies over the past decade further supporting the prognostic and predictive ability of MammaPrint and BluePrint for early stage breast cancer patients.  In addition, large, multi-institutional clinical trials, such as MINDACT and ISPY-2, can be expected to expand the assay’s clinical importance and indications for use. In the first ever prospective, observational study for a breast cancer recurrence assay, the five year prospective results of the RASTER study were published indicating that chemotherapy may be safely withheld in MammaPrint identified Low Risk breast cancer patients.  The Low Risk patient group, which primarily chose to forego chemotherapy, had a 97% distant recurrence free interval (DRFI) at 5 years.  Published studies continue to support the strong prognostic and predictive clinical utility of Agendia’s genomic assays and ongoing large, multi-site clinical trials seek to expand clinical indications for use.  

Currently, Agendia is enrolling institutions and cancer centers worldwide in the following studies:

Early stage breast cancer

  • MINT: The Multi Institutional Neo Adjuvant Therapy MammaPrint Project trial (NCT01501487)
  • PROMIS: PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score (NCT01617954)
  • NBRST: Neo-adjuvant Breast Registry Symphony Trial (NCT01479101) [Open, not currently enrolling or adding new institutions]

Early stage colon cancer

  • PARSC : A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrint (NCT00903565)

With Agendia’s state-of-the-art genomics laboratories in California and the Netherlands, the company is actively engaging academic centers, medical institutions and pharmaceutical companies in clinical trials collaboration opportunities, globally.

For more information on Agendia’s clinical study opportunities, please contact Agendia Medical Affairs at clinicaltrials@agendia.com.

What is genomic testing?

Genomic tests look at your specific tumor’s genes, to help find out what’s driving its growth.  Using gene expression testing to help design a tailored treatment plan is called personalized medicine.  These are not the same as genetic tests that determine your inherited risk or hereditary predisposition for cancer.

Your physician will assess many factors prior to determining your treatment plan, including the size of the tumor, lymph node involvement, and the hormone receptor status of your cancer.  These factors, along with your tumor’s genomic profile, can help you and your physician make the most informed treatment decisions for your specific type of cancer.

Your tumor is unique, your treatment should be too

JOIN A SUPPORT GROUP

Learn more about breast cancer treatment by visiting www.knowyourbreastcancer.com or connect with a support group through the Symphony Sisterhood on Facebook